-
J Thorac Oncol: Efficacy and safety of Durvalumab + tremelimumab combined with or without chemotherapy in the first-line treatment of metastatic NSCLC patients with negative driver genes
Time of Update: 2021-12-03
Recently, a study was published in the journal J Thorac Oncol, comparing the efficacy and safety of durvalumab + tremelimumab combined with or without chemotherapy in the first-line treatment of metastatic NSCLC patients with negative driver genes .
-
Thorac Cancer: The efficacy of dacomitinib in the treatment of EGFR mutation-positive NSCLC patients with brain metastases in the real world
Time of Update: 2021-12-03
NSCLCThe study included 32 patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations and brain metastases, all receiving dacomitinib treatment .
The study included 32 patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations and brain metastases, all receiving dacomitinib treatment .
-
Front Oncol: The efficacy of initial laparoscopic surgery (PLA) and open surgery (OA) in the treatment of T1b/T2 stage gallbladder cancer (GBC) patients
Time of Update: 2021-12-03
Subgroup analysis was used to determine the significant risk factors related to OS/DFS in patients with GBC treated with PLA/OA .
Subgroup analysis was used to determine the significant risk factors related to OS/DFS in patients with GBC treated with PLA/OA .
-
J Clin Oncol: Effectiveness of Fnettopitant vs Fosapreitant in preventing chemotherapy-induced nausea and vomiting
Time of Update: 2021-12-03
Fosaprepitant (Fosaprepitant, FosAPR) combined with Palonol, head-to-head The effectiveness and safety of setron and dexamethasone in preventing nausea and vomiting caused by highly emetic chemotherapy .
Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE .
-
Clin Cancer Res: Application of OX40 agonist Ivuxolimab in patients with locally advanced or metastatic cancer
Time of Update: 2021-12-03
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers .
-
Radiology: Breast MRI during neoadjuvant chemotherapy must pay attention to this sign!
Time of Update: 2021-12-03
In addition, it can also be vascularRecently, a study published in the journal Radiology explored the relationship between the lack of BPE inhibition and NAC treatment response in HR-positive and HR-negative cohorts, providing a reference for accurate disease identification and further evaluation of treatment effects .
-
Nature: New CAR-T therapy is expected to target various types of cancer
Time of Update: 2021-12-03
The study used large data sets and advanced algorithms to identify that the neuroblastoma immune peptide group is rich in protein peptides that are essential for tumorigenesis, and focuses on human leukocyte antigen ( HLA ) -A*24:02 The unmutated peptide found on QYNPIRTTF , which is derived from neuroblastoma-dependent genes and the core transcription regulator PHOX2B , and can be carried by the " peptide-centric " chimeric antigen receptor ( PC-CAR ) Targeted therapy .
-
Science Sub-Journal: First discovery that insomnia is a potential risk factor for fatal cerebral aneurysm rupture
Time of Update: 2021-12-03
A recent study in the Journal of the American Heart Association entitled "Modifiable Risk Factors for Intracranial Aneurysm and Aneurysmal Subarachnoid Hemorrhage: A Mendelian Randomization Study" shows that insomnia may be a potential risk of fatal cerebral aneurysm rupture and bleeding Factors .
-
J Urol: Can blue light cystoscopy improve the detection rate of recurrence in patients with non-muscular invasive bladder cancer?
Time of Update: 2021-12-03
Recently, researchers from the United States published an article in "J Urol" magazine to determine whether BLC can improve the detection rate of recurrence in patients receiving BCG treatment of non-muscle invasive bladder cancer (NMIBC) .
-
Nat Commun: Wang Lidong's team at Zhengzhou University reveals that cardiac cancer in northern China may be related to diet
Time of Update: 2021-12-03
Recently, the State Key Laboratory of Esophageal Cancer Prevention and Treatment was jointly established by Zhengzhou University, the team of Professor Wang Lidong of the First Affiliated Hospital of Zhengzhou University, and the team of Professor Chen Xingqi of Uppsala University in Sweden, and published the title in Nature Communications, a sub-Journal of Nature: Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia denocarcinoma .
-
Clin Cancer Res: Oral Selinexor for the treatment of recurrent glioblastoma
Time of Update: 2021-12-03
For adult patients with recurrent glioblastoma, a single dose of 80 mg selinexor per week can induce remission, improve the patient's clinical relative progression-free survival rate, and controllable side effects .
-
Clin Cancer Res: The effect of multi-receptor tyrosine kinase inhibitor cabotinib as a single agent in the treatment of advanced soft tissue sarcoma
Time of Update: 2021-12-03
Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft tissue sarcomas .
CCR-21-2480Clinical activity of single-agent cabozantinib ( XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft tissue sarcomas in this message
-
Science Translational Medicine: Knock out this epigenetic gene to make CAR-T more effective
Time of Update: 2021-12-03
The study showed that knocking out the DNA methyltransferase 3α (DNMT3A) gene of CAR-T cells can prevent T cell exhaustion and enhance anti-tumor activity .
-
Clin Cancer Res: Treatment-free survival after immune + targeted therapy in advanced renal cell carcinoma
Time of Update: 2021-12-03
7 months)In summary, regardless of the patient's risk, compared with the sunitinib group, patients with advanced renal cell carcinoma treated with nivolumab combined with ipilimumab have significantly longer survival times without additional treatment without immune side effects .
-
Front Oncol: Surgeons' proficiency in minimally invasive surgery affects the prognosis of patients with early cervical cancer: a retrospective study of 851 patients
Time of Update: 2021-12-03
Recently, Frontiers in Oncology published a study by the Sichuan University research team to compare the clinical efficacy of minimally invasive surgery (MIS) in patients with early cervical cancer and assess whether the proficiency of surgeons affects survival .
-
Eur J Cancer: In HER2-positive early operable breast cancer patients, the efficacy and predictive markers of trastuzumab combined with everolimus before surgery
Time of Update: 2021-12-03
The clinical remission rates of trastuzumab (T) and trastuzumab combined with everolimus (T+E) groups were 34.
The clinical remission rates of trastuzumab (T) and trastuzumab combined with everolimus (T+E) groups were 34.
The clinical remission rates of trastuzumab (T) and trastuzumab combined with everolimus (T+E) groups were 34.
-
Clin Cancer Res: Efficacy of high-dose IL-2 combined with stereotactic ablation radiotherapy in the treatment of metastatic renal cell carcinoma
Time of Update: 2021-12-03
immunityThis is a phase II clinical trial to evaluate whether additional stereotactic ablation radiotherapy (SAbR) can promote tumor antigen presentation and improve the overall response rate of patients with metastatic renal cell carcinoma to high-dose IL2 (HR IL2) .
-
Eur Heart J: Incidence, risk factors and death of atrial fibrillation in breast cancer patients
Time of Update: 2021-12-03
Recently, the heart blood vessels magazine field authority Eur Heart published a research article on J, the purpose of this study was to evaluate breast cancer patients nationwide AF incidence, risk factors and related mortality .
-
J Clin Oncol: The effectiveness and safety of neurokinin-1 receptor antagonist fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) in preventing nausea and vomiting caused by hyperemetic chemotherapy
Time of Update: 2021-12-03
Recently, a phase III clinical study was published in the Journal of Clinical Oncology, comparing two neurokinin-1 receptor antagonists fosnetupitant (FosNTP) and fosaprepitant (FosAPR) combined with palonosetron and dexamethasone head-to-head Effectiveness and safety of preventing nausea and vomiting caused by highly emetic chemotherapy .
-
J Urol: In non-muscular invasive bladder cancer, can lymphadenectomy improve the therapeutic effect of radical cystectomy?
Time of Update: 2021-12-03
Recently, researchers from the United States published an article in "J Urol", evaluating the relationship between LND and local pelvic recurrence-free survival (LPRS), cancer-specific survival (CSS), and overall survival (OS) during the RC period of NMIBC.
